CStone Pharmaceuticals Management
Management criteria checks 1/4
CStone Pharmaceuticals' CEO is Jason Yang, appointed in Aug 2022, has a tenure of 1.75 years. total yearly compensation is CN¥61.90M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.91% of the company’s shares, worth HK$10.16M. The average tenure of the management team and the board of directors is 1.8 years and 5.2 years respectively.
Key information
Jason Yang
Chief executive officer
CN¥61.9m
Total compensation
| CEO salary percentage | 4.1% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.9% |
| Management average tenure | 1.8yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04
Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Analysts Expect Breakeven For CStone Pharmaceuticals (HKG:2616) Before Long
Apr 29What Kind Of Shareholders Own CStone Pharmaceuticals (HKG:2616)?
Mar 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥367m |
| Sep 30 2023 | n/a | n/a | -CN¥559m |
| Jun 30 2023 | n/a | n/a | -CN¥750m |
| Mar 31 2023 | n/a | n/a | -CN¥827m |
| Dec 31 2022 | CN¥62m | CN¥3m | -CN¥903m |
Compensation vs Market: Jason's total compensation ($USD8.55M) is above average for companies of similar size in the Hong Kong market ($USD233.89K).
Compensation vs Earnings: Insufficient data to compare Jason's compensation with company performance.
CEO
Jason Yang (59 yo)
1.8yrs
Tenure
CN¥61,895,000
Compensation
Dr. Jianxin Yang, M.D., Ph D., also known as Jason, serves as President of R&D of CStone Pharmaceuticals since 2024 and was Senior Vice President and Chief Medical Officer December 2016 until 2024 and has...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO and President of R&D | 1.8yrs | CN¥61.90m | 0.91% CN¥ 10.2m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Senior VP & Chief Scientific Officer | no data | no data | no data | |
| Chief Commercial Officer & Chief Strategy Officer | 3yrs | no data | no data | |
| Head of Commercial | less than a year | no data | no data | |
| Joint Company Secretary | 1.8yrs | no data | no data |
1.8yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 2616's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Scientific Advisory Board | 5.2yrs | no data | no data | |
| Independent Non-Executive Director | 5.3yrs | CN¥269.00k | no data | |
| Non-Executive Director | 3.5yrs | no data | no data | |
| Independent Non-Executive Director | 5.3yrs | CN¥673.00k | no data | |
| Non Executive Director | 2.4yrs | CN¥399.00k | no data | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data | |
| Independent Non-Executive Director | 5.3yrs | CN¥269.00k | no data | |
| Non-Executive Chairman | 8.4yrs | no data | no data | |
| Non-Executive Director | 2.8yrs | no data | no data |
5.2yrs
Average Tenure
61yo
Average Age
Experienced Board: 2616's board of directors are considered experienced (5.2 years average tenure).